Novo Nordisk A/S (LON:0QIU)
London · Delayed Price · Currency is GBP · Price in DKK | Market Cap | 153.41B -35.7% |
| Revenue (ttm) | 38.30B +8.1% |
| Net Income | 14.25B +16.6% |
| EPS | 3.20 +16.8% |
| Shares Out | n/a |
| PE Ratio | 10.77 |
| Forward PE | 14.70 |
| Dividend | 1.36 (0.46%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | 1,321,866 |
| Open | 292.00 |
| Previous Close | 293.31 |
| Day's Range | 287.05 - 300.10 |
| 52-Week Range | 224.55 - 492.70 |
| Beta | 0.24 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
South Africa court bars iDexis from selling compounded Ozempic in Novo Nordisk case
South Africa's High Court has granted Novo Nordisk an interim interdict barring a local pharmacy group from manufacturing and selling compounded weight-loss medicines containing semaglutide, in a ...
Doctors say that GLP-1 medications can prevent lifelong obesity and Type 2 diabetes in children—but there are some worries
Doctors are looking for better options given the growing awareness of the serious health risks tied to childhood obesity.
Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock?
Novo Nordisk was the first to market with a GLP-1 weight-loss drug. It lost its early lead to Eli Lilly, which is now the name to beat in the GLP-1 race.
Novo Nordisk Stock Climbs as Analyst Flags Potential for More Wegovy Pill Sales
Novo Nordisk’s ($NVO) shares in Copenhagen closed roughly 5% higher on Friday. This came after Nordea ($NRDBY) went bullish on the Danish drugmaker, upgrading its NVO rating from Hold to…
Novo Nordisk Stock Rally as Owner Unveils $69 Million Obesity Research Push
Novo Nordisk Stock Rally as Owner Unveils $69 Million Obesity Research Push
Sumitomo Pharma, Novo Nordisk Win Japan Nod For Wegovy In MASH
(RTTNews) - Sumitomo Pharma Co., Ltd. (4506.T) announced on Friday that Japan has cleared Wegovy Subcutaneous Injection, which it co-promotes with Novo Nordisk B A/S (NVO), to treat metabolic dysfunct...
Novo Nordisk Rises as Foundation Launches EUR 60 Million Incubator
Novo Nordisk Rises as Foundation Launches EUR 60 Million Incubator
Novo Nordisk upgraded to Buy from Hold at Nordea
Nordea upgraded Novo Nordisk (NVO) to Buy from Hold with a DKK 350 price target The firm believes the near-term news flow “looks positively skewed.” Nordea sees potential for Novo’s…
Novo Nordisk Stock Jumps as Owner Launches Obesity Research Network
Danish drugmaker Novo Nordisk’s ($NVO) shares in Copenhagen rose about 5% on Friday. This coincides with Novo Nordisk Foundation, the company’s majority owner, launching a pan-European initiative to s...
After Novo Nordisk's Oral Peptide Playbook Made History -- Could Entera be The Next Big Peptide ...
After Novo Nordisk's Oral Peptide Playbook Made History -- Could Entera be The Next Big Peptide Story?
Novo Nordisk Faces Alleged Data Theft After Cyber Extortion Group Claims Massive Breach
(RTTNews) - Novo Nordisk B A/S (NVO), the Danish pharmaceutical firm, has announced it's looking into claims made by the cyber extortion group FulcrumSec, which alleges that over a terabyte of company...
NVO: Novo Nordisk Targets Chinese Market with Wegovy Filing
NVO: Novo Nordisk Targets Chinese Market with Wegovy Filing
Novo Nordisk (NVO) Plans to Submit Wegovy for Approval in China
Novo Nordisk (NVO) Plans to Submit Wegovy for Approval in China
Novo Nordisk price target raised to DKK 325 from DKK 300 at Berenberg
Berenberg analyst Kerry Holford raised the firm’s price target on Novo Nordisk (NVO) to DKK 325 from DKK 300 and keeps a Buy rating on the shares. Published first on…
Ozempic Linked To Lower Risk Of Violence In New Study
The researchers said the findings are not causal and urged more research into whether GLP-1s reduce the risk of violence. Daniel Semenza, lead author of the study and director of research at the New J...
Europe’s biggest pharma company Novo Nordisk ‘hacked’
Novo Nordisk, Europe's largest pharmaceutical company, has been targeted by cyber extortion group FulcrumSec. The group claims to have infiltrated Novo Nordisk's network for over two months, stealing ...
Hacking group claims major hack of Novo Nordisk and attempted $25m extortion
FulcrumSec Claims Data Theft from Novo Nordisk, Seeks $25M Ransom
FulcrumSec Claims Data Theft from Novo Nordisk, Seeks $25M Ransom
Hacking group claims major hack of Novo Nordisk and attempted $25 million extortion
A cyber extortion group claimed on Tuesday to have stolen more than a terabyte of data from pharmaceutical giant Novo Nordisk and said it is exploring selling parts of the data after unsuccessfully ...
Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock?
Eli Lilly currently leads the weight loss market. Novo Nordisk's newer launches could help it make up some ground.
Novo Nordisk to File Oral Wegovy in China
Novo Nordisk to File Oral Wegovy in China
Novo Nordisk Plans to Seek Approval for Wegovy in China
Novo Nordisk Plans to Seek Approval for Wegovy in China
Novo Nordisk Seeks China Approval for Wegovy Pill, Intensifying Rivalry with Lilly
Novo Nordisk ($NVO) is stepping up its competition with rival Eli Lilly ($LLY) in China’s oral weight loss drug market. According to a Reuters report, CEO Mike Doustdar said the…
Novo Nordisk to seek regulatory approval for Wegovy pill in China soon, says CEO
Novo Nordisk plans to seek Chinese regulatory approval for its weight-loss pill "very soon," CEO Mike Doustdar said Tuesday, in a move to catch up with rival Eli Lilly in the world's s...
How LLY Overtook NVO in GLP-1 Space & Offering LLY Options Trade
The GLP-1 race "is not fair to call a race anymore," argues Scott Zari when comparing Eli Lilly (LLY) and Novo Nordisk (NVO), calling the former a clear winner. He explains how Eli Lilly pulled ahead ...